免疫抑制薬のグローバル市場インサイト・予測（～2028年）

• 英文タイトル：Global Immunosuppressive Drugs Market Insights, Forecast to 2028

• レポートコード：QY2207E10383 • 出版社/出版日：QYResearch / 2022年7月 • レポート形態：英文、PDF、106ページ • 納品方法：Eメール（納期：3日） • 産業分類：医薬品

• 販売価格（消費税別）

Single User	￥735,000 (USD4,900)	▷ お問い合わせ
Multi User	￥1,102,500 (USD7,350)	▷ お問い合わせ
Enterprise License	￥1,470,000 (USD9,800)	▷ お問い合わせ

• ご注文方法：お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法：銀行振込（納品後、ご請求書送付）

---

レポート概要

---

新型コロナウイルス感染症のパンデミックにより、世界の免疫抑制薬の市場規模は2022年にUS$xxxと推定され、調査期間中のCAGRはxxx％で、2028年までに再調整された規模はUS$xxxになると予測されています。この医療危機による経済変化を十分に考慮すると、2021年に免疫抑制薬の世界市場のxxx％を占める「カルシニューリン阻害剤」タイプは、2028年までにUS$xxxの規模になり、パンデミック後の修正xxx％CAGRで成長すると予測されています。一方、「腎臓移植」セグメントは、この予測期間を通じてxxx％のCAGRに変更されます。 中国の免疫抑制薬の市場規模は2021年にUS$xxxと分析されており、米国とヨーロッパの免疫抑制薬市場規模はそれぞれUS$xxxとUS$xxxです。米国の割合は2021年にxxx％であり、中国とヨーロッパはそれぞれxxx％とxxx％です。中国の割合は2028年にxxx％に達し、対象期間を通じてxxx％のCAGRを記録すると予測されています。日本、韓国、東南アジアはアジアで注目市場であり、今後6年間のCAGRはそれぞれxxx％、xxx％、xxx％になる見通しです。ヨーロッパの免疫抑制薬市場については、ドイツは2028年までにUS$xxxに達すると予測されており、予測期間中のCAGRはxxx％になる見通しです。 免疫抑制薬のグローバル主要メーカーには、Pfizer、Sanofi、Novartis、Roche、Astellas Pharma, Inc.、GlaxoSmithKline plc、Veloxis Pharmaceuticals、Mylan、Dr Reddys Laboratories、Abbvie Incなどがあります。2021年、世界のトップ5プレイヤーは売上ベースで約xxx％の市場シェアを占めています。 免疫抑制薬市場は、種類と用途によって区分されます。世界の免疫抑制薬市場のプレーヤー、利害関係者、およびその他の参加者は、当レポートを有益なリソースとして使用することで優位に立つことができます。セグメント分析は、2017年～2028年期間のタイプ別および用途別の販売量、売上、予測に焦点を当てています。 【種類別セグメント】 カルシニューリン阻害剤、抗増殖剤、mTOR阻害剤、抗体、ステロイド 【用途別セグメント】 腎臓移植、骨骨髄移植、肝臓移植、心臓移植、肺移植、その他移植 【掲載地域】 北米：アメリカ、カナダ ヨーロッパ：ドイツ、フランス、イギリス、イタリア、ロシア アジア太平洋：日本、中国、韓国、インド、オーストラリア、台湾、インドネシア、タイ、マレーシア 中南米：メキシコ、ブラジル、アルゼンチン 中東・アフリカ：トルコ、サウジアラビア、UAE 【目次（一部）】 ・調査の範囲 - 免疫抑制薬製品概要 - 種類別市場（カルシニューリン阻害剤、抗増殖剤、mTOR阻害剤、抗体、ステロイド） - 用途別市場（腎臓移植、骨骨髄移植、肝臓移植、心臓移植、肺移植、その他移植） - 調査の目的 ・エグゼクティブサマリー - 世界の免疫抑制薬販売量予測2017-2028 - 世界の免疫抑制薬売上予測2017-2028 - 免疫抑制薬の地域別販売量 - 免疫抑制薬の地域別売上 - 北米市場 - ヨーロッパ市場 - アジア太平洋市場 - 中南米市場 - 中東・アフリカ市場 ・メーカーの競争状況 - 主要メーカー別免疫抑制薬販売量 - 主要メーカー別免疫抑制薬売上 - 主要メーカー別免疫抑制薬価格 - 競争状況の分析 - 企業M&A動向 ・種類別市場規模（カルシニューリン阻害剤、抗増殖剤、mTOR阻害剤、抗体、ステロイド） - 免疫抑制薬の種類別販売量 - 免疫抑制薬の種類別売上 - 免疫抑制薬の種類別価格 ・用途別市場規模（腎臓移植、骨骨髄移植、肝臓移植、心臓移植、肺移植、その他移植） - 免疫抑制薬の用途別販売量 - 免疫抑制薬の用途別売上 - 免疫抑制薬の用途別価格 ・北米市場 - 北米の免疫抑制薬市場規模（種類別、用途別） - 主要国別の免疫抑制薬市場規模（アメリカ、カナダ） ・ヨーロッパ市場 - ヨーロッパの免疫抑制薬市場規模（種類別、用途別） - 主要国別の免疫抑制薬市場規模（ドイツ、フランス、イギリス、イタリア、ロシア） ・アジア太平洋市場 - アジア太平洋の免疫抑制薬市場規模（種類別、用途別） - 主要国別の免疫抑制薬市場規模（日本、中国、韓国、インド、オーストラリア、台湾、インドネシア、タイ、マレーシア） ・中南米市場 - 中南米の免疫抑制薬市場規模（種類別、用途別） - 主要国別の免疫抑制薬市場規模（メキシコ、ブラジル、アルゼンチン） ・中東・アフリカ市場 - 中東・アフリカの免疫抑制薬市場規模（種類別、用途別） - 主要国別の免疫抑制薬市場規模（トルコ、サウジアラビア） ・企業情報 Pfizer、Sanofi、Novartis、Roche、Astellas Pharma, Inc.、GlaxoSmithKline plc、Veloxis Pharmaceuticals、Mylan、Dr Reddys Laboratories、Abbvie Inc ・産業チェーン及び販売チャネル分析 - 免疫抑制薬の産業チェーン分析 - 免疫抑制薬の原材料 - 免疫抑制薬の生産プロセス - 免疫抑制薬の販売及びマーケティング - 免疫抑制薬の主要顧客 ・マーケットドライバー、機会、課題、リスク要因分析 - 免疫抑制薬の産業動向 - 免疫抑制薬のマーケットドライバー - 免疫抑制薬の課題 - 免疫抑制薬の阻害要因 ・主な調査結果

Market Analysis and Insights: Global Immunosuppressive Drugs Market
Due to the COVID-19 pandemic, the global Immunosuppressive Drugs market size is estimated to be worth US$ million in 2022 and is forecast to a readjusted size of US$ million by 2028 with a CAGR of % during the forecast period 2022-2028. Fully considering the economic change by this health crisis, Calcineurin Inhibitors accounting for % of the Immunosuppressive Drugs global market in 2021, is projected to value US$ million by 2028, growing at a revised % CAGR from 2022 to 2028. While Kidney Transplant segment is altered to an % CAGR throughout this forecast period.
China Immunosuppressive Drugs market size is valued at US$ million in 2021, while the US and Europe Immunosuppressive Drugs are US$ million and US$ million, severally. The proportion of the US is % in 2021, while China and Europe are % and % respectively, and it is predicted that China proportion will reach % in 2028, trailing a CAGR of % through the analysis period 2022-2028. Japan, South Korea, and Southeast Asia are noteworthy markets in Asia, with CAGR %, %, and % respectively for the next 6-year period. As for the Europe Immunosuppressive Drugs landscape, Germany is projected to reach US$ million by 2028 trailing a CAGR of % over the forecast period 2022-2028.
The global key manufacturers of Immunosuppressive Drugs include Pfizer, Sanofi, Novartis, Roche, Astellas Pharma, Inc., GlaxoSmithKline plc, Veloxis Pharmaceuticals, Mylan and Dr Reddys Laboratories and etc. In 2021, the global top five players have a share approximately % in terms of revenue.
Global Immunosuppressive Drugs Scope and Segment
Immunosuppressive Drugs market is segmented by Type and by Application. Players, stakeholders, and other participants in the global Immunosuppressive Drugs market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by Type and by Application for the period 2017-2028.
Segment by Type
Calcineurin Inhibitors
Antiproliferative Agents
mTOR Inhibitors
Antibodies
Steroids
Segment by Application
Kidney Transplant
Bone Marrow Transplant
Liver Transplant
Heart Transplant
Lungs Transplant
Others Transplant
By Company
Pfizer
Sanofi
Novartis
Roche
Astellas Pharma, Inc.
GlaxoSmithKline plc
Veloxis Pharmaceuticals
Mylan
Dr Reddys Laboratories
Abbvie Inc
By Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE

レポート目次

---

1 Study Coverage
1.1 Immunosuppressive Drugs Product Introduction
1.2 Market by Type
1.2.1 Global Immunosuppressive Drugs Market Size Growth Rate by Type, 2017 VS 2021 VS 2028
1.2.2 Calcineurin Inhibitors
1.2.3 Antiproliferative Agents
1.2.4 mTOR Inhibitors
1.2.5 Antibodies
1.2.6 Steroids
1.3 Market by Application
1.3.1 Global Immunosuppressive Drugs Market Size Growth Rate by Application, 2017 VS 2021 VS 2028
1.3.2 Kidney Transplant
1.3.3 Bone Marrow Transplant
1.3.4 Liver Transplant
1.3.5 Heart Transplant
1.3.6 Lungs Transplant
1.3.7 Others Transplant
1.4 Study Objectives
1.5 Years Considered
2 Executive Summary
2.1 Global Immunosuppressive Drugs Sales Estimates and Forecasts 2017-2028
2.2 Global Immunosuppressive Drugs Revenue Estimates and Forecasts 2017-2028
2.3 Global Immunosuppressive Drugs Revenue by Region: 2017 VS 2021 VS 2028
2.4 Global Immunosuppressive Drugs Sales by Region
2.4.1 Global Immunosuppressive Drugs Sales by Region (2017-2022)
2.4.2 Global Sales Immunosuppressive Drugs by Region (2023-2028)
2.5 Global Immunosuppressive Drugs Revenue by Region
2.5.1 Global Immunosuppressive Drugs Revenue by Region (2017-2022)
2.5.2 Global Immunosuppressive Drugs Revenue by Region (2023-2028)
2.6 North America
2.7 Europe
2.8 Asia-Pacific
2.9 Latin America
2.10 Middle East & Africa
3 Competition by Manufacturers
3.1 Global Immunosuppressive Drugs Sales by Manufacturers
3.1.1 Global Top Immunosuppressive Drugs Manufacturers by Sales (2017-2022)
3.1.2 Global Immunosuppressive Drugs Sales Market Share by Manufacturers (2017-2022)
3.1.3 Global Top 10 and Top 5 Largest Manufacturers of Immunosuppressive Drugs in 2021
3.2 Global Immunosuppressive Drugs Revenue by Manufacturers
3.2.1 Global Immunosuppressive Drugs Revenue by Manufacturers (2017-2022)
3.2.2 Global Immunosuppressive Drugs Revenue Market Share by Manufacturers (2017-2022)
3.2.3 Global Top 10 and Top 5 Companies by Immunosuppressive Drugs Revenue in 2021
3.3 Global Immunosuppressive Drugs Sales Price by Manufacturers (2017-2022)
3.4 Analysis of Competitive Landscape
3.4.1 Manufacturers Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Immunosuppressive Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.4.3 Global Immunosuppressive Drugs Manufacturers Geographical Distribution
3.5 Mergers & Acquisitions, Expansion Plans
4 Market Size by Type
4.1 Global Immunosuppressive Drugs Sales by Type
4.1.1 Global Immunosuppressive Drugs Historical Sales by Type (2017-2022)
4.1.2 Global Immunosuppressive Drugs Forecasted Sales by Type (2023-2028)
4.1.3 Global Immunosuppressive Drugs Sales Market Share by Type (2017-2028)
4.2 Global Immunosuppressive Drugs Revenue by Type
4.2.1 Global Immunosuppressive Drugs Historical Revenue by Type (2017-2022)
4.2.2 Global Immunosuppressive Drugs Forecasted Revenue by Type (2023-2028)
4.2.3 Global Immunosuppressive Drugs Revenue Market Share by Type (2017-2028)
4.3 Global Immunosuppressive Drugs Price by Type
4.3.1 Global Immunosuppressive Drugs Price by Type (2017-2022)
4.3.2 Global Immunosuppressive Drugs Price Forecast by Type (2023-2028)
5 Market Size by Application
5.1 Global Immunosuppressive Drugs Sales by Application
5.1.1 Global Immunosuppressive Drugs Historical Sales by Application (2017-2022)
5.1.2 Global Immunosuppressive Drugs Forecasted Sales by Application (2023-2028)
5.1.3 Global Immunosuppressive Drugs Sales Market Share by Application (2017-2028)
5.2 Global Immunosuppressive Drugs Revenue by Application
5.2.1 Global Immunosuppressive Drugs Historical Revenue by Application (2017-2022)
5.2.2 Global Immunosuppressive Drugs Forecasted Revenue by Application (2023-2028)
5.2.3 Global Immunosuppressive Drugs Revenue Market Share by Application (2017-2028)
5.3 Global Immunosuppressive Drugs Price by Application
5.3.1 Global Immunosuppressive Drugs Price by Application (2017-2022)
5.3.2 Global Immunosuppressive Drugs Price Forecast by Application (2023-2028)
6 North America
6.1 North America Immunosuppressive Drugs Market Size by Type
6.1.1 North America Immunosuppressive Drugs Sales by Type (2017-2028)
6.1.2 North America Immunosuppressive Drugs Revenue by Type (2017-2028)
6.2 North America Immunosuppressive Drugs Market Size by Application
6.2.1 North America Immunosuppressive Drugs Sales by Application (2017-2028)
6.2.2 North America Immunosuppressive Drugs Revenue by Application (2017-2028)
6.3 North America Immunosuppressive Drugs Market Size by Country
6.3.1 North America Immunosuppressive Drugs Sales by Country (2017-2028)
6.3.2 North America Immunosuppressive Drugs Revenue by Country (2017-2028)
6.3.3 United States
6.3.4 Canada
7 Europe
7.1 Europe Immunosuppressive Drugs Market Size by Type
7.1.1 Europe Immunosuppressive Drugs Sales by Type (2017-2028)
7.1.2 Europe Immunosuppressive Drugs Revenue by Type (2017-2028)
7.2 Europe Immunosuppressive Drugs Market Size by Application
7.2.1 Europe Immunosuppressive Drugs Sales by Application (2017-2028)
7.2.2 Europe Immunosuppressive Drugs Revenue by Application (2017-2028)
7.3 Europe Immunosuppressive Drugs Market Size by Country
7.3.1 Europe Immunosuppressive Drugs Sales by Country (2017-2028)
7.3.2 Europe Immunosuppressive Drugs Revenue by Country (2017-2028)
7.3.3 Germany
7.3.4 France
7.3.5 U.K.
7.3.6 Italy
7.3.7 Russia
8 Asia Pacific
8.1 Asia Pacific Immunosuppressive Drugs Market Size by Type
8.1.1 Asia Pacific Immunosuppressive Drugs Sales by Type (2017-2028)
8.1.2 Asia Pacific Immunosuppressive Drugs Revenue by Type (2017-2028)
8.2 Asia Pacific Immunosuppressive Drugs Market Size by Application
8.2.1 Asia Pacific Immunosuppressive Drugs Sales by Application (2017-2028)
8.2.2 Asia Pacific Immunosuppressive Drugs Revenue by Application (2017-2028)
8.3 Asia Pacific Immunosuppressive Drugs Market Size by Region
8.3.1 Asia Pacific Immunosuppressive Drugs Sales by Region (2017-2028)
8.3.2 Asia Pacific Immunosuppressive Drugs Revenue by Region (2017-2028)
8.3.3 China
8.3.4 Japan
8.3.5 South Korea
8.3.6 India
8.3.7 Australia
8.3.8 China Taiwan
8.3.9 Indonesia
8.3.10 Thailand
8.3.11 Malaysia
9 Latin America
9.1 Latin America Immunosuppressive Drugs Market Size by Type
9.1.1 Latin America Immunosuppressive Drugs Sales by Type (2017-2028)
9.1.2 Latin America Immunosuppressive Drugs Revenue by Type (2017-2028)
9.2 Latin America Immunosuppressive Drugs Market Size by Application
9.2.1 Latin America Immunosuppressive Drugs Sales by Application (2017-2028)
9.2.2 Latin America Immunosuppressive Drugs Revenue by Application (2017-2028)
9.3 Latin America Immunosuppressive Drugs Market Size by Country
9.3.1 Latin America Immunosuppressive Drugs Sales by Country (2017-2028)
9.3.2 Latin America Immunosuppressive Drugs Revenue by Country (2017-2028)
9.3.3 Mexico
9.3.4 Brazil
9.3.5 Argentina
10 Middle East and Africa
10.1 Middle East and Africa Immunosuppressive Drugs Market Size by Type
10.1.1 Middle East and Africa Immunosuppressive Drugs Sales by Type (2017-2028)
10.1.2 Middle East and Africa Immunosuppressive Drugs Revenue by Type (2017-2028)
10.2 Middle East and Africa Immunosuppressive Drugs Market Size by Application
10.2.1 Middle East and Africa Immunosuppressive Drugs Sales by Application (2017-2028)
10.2.2 Middle East and Africa Immunosuppressive Drugs Revenue by Application (2017-2028)
10.3 Middle East and Africa Immunosuppressive Drugs Market Size by Country
10.3.1 Middle East and Africa Immunosuppressive Drugs Sales by Country (2017-2028)
10.3.2 Middle East and Africa Immunosuppressive Drugs Revenue by Country (2017-2028)
10.3.3 Turkey
10.3.4 Saudi Arabia
11 Company Profiles
11.1 Pfizer
11.1.1 Pfizer Corporation Information
11.1.2 Pfizer Overview
11.1.3 Pfizer Immunosuppressive Drugs Sales, Price, Revenue and Gross Margin (2017-2022)
11.1.4 Pfizer Immunosuppressive Drugs Product Model Numbers, Pictures, Descriptions and Specifications
11.1.5 Pfizer Recent Developments
11.2 Sanofi
11.2.1 Sanofi Corporation Information
11.2.2 Sanofi Overview
11.2.3 Sanofi Immunosuppressive Drugs Sales, Price, Revenue and Gross Margin (2017-2022)
11.2.4 Sanofi Immunosuppressive Drugs Product Model Numbers, Pictures, Descriptions and Specifications
11.2.5 Sanofi Recent Developments
11.3 Novartis
11.3.1 Novartis Corporation Information
11.3.2 Novartis Overview
11.3.3 Novartis Immunosuppressive Drugs Sales, Price, Revenue and Gross Margin (2017-2022)
11.3.4 Novartis Immunosuppressive Drugs Product Model Numbers, Pictures, Descriptions and Specifications
11.3.5 Novartis Recent Developments
11.4 Roche
11.4.1 Roche Corporation Information
11.4.2 Roche Overview
11.4.3 Roche Immunosuppressive Drugs Sales, Price, Revenue and Gross Margin (2017-2022)
11.4.4 Roche Immunosuppressive Drugs Product Model Numbers, Pictures, Descriptions and Specifications
11.4.5 Roche Recent Developments
11.5 Astellas Pharma, Inc.
11.5.1 Astellas Pharma, Inc. Corporation Information
11.5.2 Astellas Pharma, Inc. Overview
11.5.3 Astellas Pharma, Inc. Immunosuppressive Drugs Sales, Price, Revenue and Gross Margin (2017-2022)
11.5.4 Astellas Pharma, Inc. Immunosuppressive Drugs Product Model Numbers, Pictures, Descriptions and Specifications
11.5.5 Astellas Pharma, Inc. Recent Developments
11.6 GlaxoSmithKline plc
11.6.1 GlaxoSmithKline plc Corporation Information
11.6.2 GlaxoSmithKline plc Overview
11.6.3 GlaxoSmithKline plc Immunosuppressive Drugs Sales, Price, Revenue and Gross Margin (2017-2022)
11.6.4 GlaxoSmithKline plc Immunosuppressive Drugs Product Model Numbers, Pictures, Descriptions and Specifications
11.6.5 GlaxoSmithKline plc Recent Developments
11.7 Veloxis Pharmaceuticals
11.7.1 Veloxis Pharmaceuticals Corporation Information
11.7.2 Veloxis Pharmaceuticals Overview
11.7.3 Veloxis Pharmaceuticals Immunosuppressive Drugs Sales, Price, Revenue and Gross Margin (2017-2022)
11.7.4 Veloxis Pharmaceuticals Immunosuppressive Drugs Product Model Numbers, Pictures, Descriptions and Specifications
11.7.5 Veloxis Pharmaceuticals Recent Developments
11.8 Mylan
11.8.1 Mylan Corporation Information
11.8.2 Mylan Overview
11.8.3 Mylan Immunosuppressive Drugs Sales, Price, Revenue and Gross Margin (2017-2022)
11.8.4 Mylan Immunosuppressive Drugs Product Model Numbers, Pictures, Descriptions and Specifications
11.8.5 Mylan Recent Developments
11.9 Dr Reddys Laboratories
11.9.1 Dr Reddys Laboratories Corporation Information
11.9.2 Dr Reddys Laboratories Overview
11.9.3 Dr Reddys Laboratories Immunosuppressive Drugs Sales, Price, Revenue and Gross Margin (2017-2022)
11.9.4 Dr Reddys Laboratories Immunosuppressive Drugs Product Model Numbers, Pictures, Descriptions and Specifications
11.9.5 Dr Reddys Laboratories Recent Developments
11.10 Abbvie Inc
11.10.1 Abbvie Inc Corporation Information
11.10.2 Abbvie Inc Overview
11.10.3 Abbvie Inc Immunosuppressive Drugs Sales, Price, Revenue and Gross Margin (2017-2022)
11.10.4 Abbvie Inc Immunosuppressive Drugs Product Model Numbers, Pictures, Descriptions and Specifications
11.10.5 Abbvie Inc Recent Developments
12 Industry Chain and Sales Channels Analysis
12.1 Immunosuppressive Drugs Industry Chain Analysis
12.2 Immunosuppressive Drugs Key Raw Materials
12.2.1 Key Raw Materials
12.2.2 Raw Materials Key Suppliers
12.3 Immunosuppressive Drugs Production Mode & Process
12.4 Immunosuppressive Drugs Sales and Marketing
12.4.1 Immunosuppressive Drugs Sales Channels
12.4.2 Immunosuppressive Drugs Distributors
12.5 Immunosuppressive Drugs Customers
13 Market Drivers, Opportunities, Challenges and Risks Factors Analysis
13.1 Immunosuppressive Drugs Industry Trends
13.2 Immunosuppressive Drugs Market Drivers
13.3 Immunosuppressive Drugs Market Challenges
13.4 Immunosuppressive Drugs Market Restraints
14 Key Findings in The Global Immunosuppressive Drugs Study
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Author Details
15.3 Disclaimer

List of Tables
Table 1. Global Immunosuppressive Drugs Market Size Growth Rate by Type, 2017 VS 2021 VS 2028 (US$ Million)
Table 2. Major Manufacturers of Calcineurin Inhibitors
Table 3. Major Manufacturers of Antiproliferative Agents
Table 4. Major Manufacturers of mTOR Inhibitors
Table 5. Major Manufacturers of Antibodies
Table 6. Major Manufacturers of Steroids
Table 7. Global Immunosuppressive Drugs Market Size Growth Rate by Application, 2017 VS 2021 VS 2028 (US$ Million)
Table 8. Global Immunosuppressive Drugs Revenue by Region: 2017 VS 2021 VS 2028 (US$ Million)
Table 9. Global Immunosuppressive Drugs Sales by Region (2017-2022) & (K Units)
Table 10. Global Immunosuppressive Drugs Sales Market Share by Region (2017-2022)
Table 11. Global Immunosuppressive Drugs Sales by Region (2023-2028) & (K Units)
Table 12. Global Immunosuppressive Drugs Sales Market Share by Region (2023-2028)
Table 13. Global Immunosuppressive Drugs Revenue by Region (2017-2022) & (US$ Million)
Table 14. Global Immunosuppressive Drugs Revenue Market Share by Region (2017-2022)
Table 15. Global Immunosuppressive Drugs Revenue by Region (2023-2028) & (US$ Million)
Table 16. Global Immunosuppressive Drugs Revenue Market Share by Region (2023-2028)
Table 17. Global Immunosuppressive Drugs Sales by Manufacturers (2017-2022) & (K Units)
Table 18. Global Immunosuppressive Drugs Sales Share by Manufacturers (2017-2022)
Table 19. Global Immunosuppressive Drugs Revenue by Manufacturers (2017-2022) & (US$ Million)
Table 20. Global Immunosuppressive Drugs Revenue Share by Manufacturers (2017-2022)
Table 21. Immunosuppressive Drugs Price by Manufacturers (2017-2022) &(US$/Unit)
Table 22. Global Immunosuppressive Drugs Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 23. Global Immunosuppressive Drugs by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Immunosuppressive Drugs as of 2021)
Table 24. Immunosuppressive Drugs Manufacturing Base Distribution and Headquarters
Table 25. Manufacturers Immunosuppressive Drugs Product Offered
Table 26. Date of Manufacturers Enter into Immunosuppressive Drugs Market
Table 27. Mergers & Acquisitions, Expansion Plans
Table 28. Global Immunosuppressive Drugs Sales by Type (2017-2022) & (K Units)
Table 29. Global Immunosuppressive Drugs Sales by Type (2023-2028) & (K Units)
Table 30. Global Immunosuppressive Drugs Sales Share by Type (2017-2022)
Table 31. Global Immunosuppressive Drugs Sales Share by Type (2023-2028)
Table 32. Global Immunosuppressive Drugs Revenue by Type (2017-2022) & (US$ Million)
Table 33. Global Immunosuppressive Drugs Revenue by Type (2023-2028) & (US$ Million)
Table 34. Global Immunosuppressive Drugs Revenue Share by Type (2017-2022)
Table 35. Global Immunosuppressive Drugs Revenue Share by Type (2023-2028)
Table 36. Immunosuppressive Drugs Price by Type (2017-2022) & (US$/Unit)
Table 37. Global Immunosuppressive Drugs Price Forecast by Type (2023-2028) & (US$/Unit)
Table 38. Global Immunosuppressive Drugs Sales by Application (2017-2022) & (K Units)
Table 39. Global Immunosuppressive Drugs Sales by Application (2023-2028) & (K Units)
Table 40. Global Immunosuppressive Drugs Sales Share by Application (2017-2022)
Table 41. Global Immunosuppressive Drugs Sales Share by Application (2023-2028)
Table 42. Global Immunosuppressive Drugs Revenue by Application (2017-2022) & (US$ Million)
Table 43. Global Immunosuppressive Drugs Revenue by Application (2023-2028) & (US$ Million)
Table 44. Global Immunosuppressive Drugs Revenue Share by Application (2017-2022)
Table 45. Global Immunosuppressive Drugs Revenue Share by Application (2023-2028)
Table 46. Immunosuppressive Drugs Price by Application (2017-2022) & (US$/Unit)
Table 47. Global Immunosuppressive Drugs Price Forecast by Application (2023-2028) & (US$/Unit)
Table 48. North America Immunosuppressive Drugs Sales by Type (2017-2022) & (K Units)
Table 49. North America Immunosuppressive Drugs Sales by Type (2023-2028) & (K Units)
Table 50. North America Immunosuppressive Drugs Revenue by Type (2017-2022) & (US$ Million)
Table 51. North America Immunosuppressive Drugs Revenue by Type (2023-2028) & (US$ Million)
Table 52. North America Immunosuppressive Drugs Sales by Application (2017-2022) & (K Units)
Table 53. North America Immunosuppressive Drugs Sales by Application (2023-2028) & (K Units)
Table 54. North America Immunosuppressive Drugs Revenue by Application (2017-2022) & (US$ Million)
Table 55. North America Immunosuppressive Drugs Revenue by Application (2023-2028) & (US$ Million)
Table 56. North America Immunosuppressive Drugs Sales by Country (2017-2022) & (K Units)
Table 57. North America Immunosuppressive Drugs Sales by Country (2023-2028) & (K Units)
Table 58. North America Immunosuppressive Drugs Revenue by Country (2017-2022) & (US$ Million)
Table 59. North America Immunosuppressive Drugs Revenue by Country (2023-2028) & (US$ Million)
Table 60. Europe Immunosuppressive Drugs Sales by Type (2017-2022) & (K Units)
Table 61. Europe Immunosuppressive Drugs Sales by Type (2023-2028) & (K Units)
Table 62. Europe Immunosuppressive Drugs Revenue by Type (2017-2022) & (US$ Million)
Table 63. Europe Immunosuppressive Drugs Revenue by Type (2023-2028) & (US$ Million)
Table 64. Europe Immunosuppressive Drugs Sales by Application (2017-2022) & (K Units)
Table 65. Europe Immunosuppressive Drugs Sales by Application (2023-2028) & (K Units)
Table 66. Europe Immunosuppressive Drugs Revenue by Application (2017-2022) & (US$ Million)
Table 67. Europe Immunosuppressive Drugs Revenue by Application (2023-2028) & (US$ Million)
Table 68. Europe Immunosuppressive Drugs Sales by Country (2017-2022) & (K Units)
Table 69. Europe Immunosuppressive Drugs Sales by Country (2023-2028) & (K Units)
Table 70. Europe Immunosuppressive Drugs Revenue by Country (2017-2022) & (US$ Million)
Table 71. Europe Immunosuppressive Drugs Revenue by Country (2023-2028) & (US$ Million)
Table 72. Asia Pacific Immunosuppressive Drugs Sales by Type (2017-2022) & (K Units)
Table 73. Asia Pacific Immunosuppressive Drugs Sales by Type (2023-2028) & (K Units)
Table 74. Asia Pacific Immunosuppressive Drugs Revenue by Type (2017-2022) & (US$ Million)
Table 75. Asia Pacific Immunosuppressive Drugs Revenue by Type (2023-2028) & (US$ Million)
Table 76. Asia Pacific Immunosuppressive Drugs Sales by Application (2017-2022) & (K Units)
Table 77. Asia Pacific Immunosuppressive Drugs Sales by Application (2023-2028) & (K Units)
Table 78. Asia Pacific Immunosuppressive Drugs Revenue by Application (2017-2022) & (US$ Million)
Table 79. Asia Pacific Immunosuppressive Drugs Revenue by Application (2023-2028) & (US$ Million)
Table 80. Asia Pacific Immunosuppressive Drugs Sales by Region (2017-2022) & (K Units)
Table 81. Asia Pacific Immunosuppressive Drugs Sales by Region (2023-2028) & (K Units)
Table 82. Asia Pacific Immunosuppressive Drugs Revenue by Region (2017-2022) & (US$ Million)
Table 83. Asia Pacific Immunosuppressive Drugs Revenue by Region (2023-2028) & (US$ Million)
Table 84. Latin America Immunosuppressive Drugs Sales by Type (2017-2022) & (K Units)
Table 85. Latin America Immunosuppressive Drugs Sales by Type (2023-2028) & (K Units)
Table 86. Latin America Immunosuppressive Drugs Revenue by Type (2017-2022) & (US$ Million)
Table 87. Latin America Immunosuppressive Drugs Revenue by Type (2023-2028) & (US$ Million)
Table 88. Latin America Immunosuppressive Drugs Sales by Application (2017-2022) & (K Units)
Table 89. Latin America Immunosuppressive Drugs Sales by Application (2023-2028) & (K Units)
Table 90. Latin America Immunosuppressive Drugs Revenue by Application (2017-2022) & (US$ Million)
Table 91. Latin America Immunosuppressive Drugs Revenue by Application (2023-2028) & (US$ Million)
Table 92. Latin America Immunosuppressive Drugs Sales by Country (2017-2022) & (K Units)
Table 93. Latin America Immunosuppressive Drugs Sales by Country (2023-2028) & (K Units)
Table 94. Latin America Immunosuppressive Drugs Revenue by Country (2017-2022) & (US$ Million)
Table 95. Latin America Immunosuppressive Drugs Revenue by Country (2023-2028) & (US$ Million)
Table 96. Middle East and Africa Immunosuppressive Drugs Sales by Type (2017-2022) & (K Units)
Table 97. Middle East and Africa Immunosuppressive Drugs Sales by Type (2023-2028) & (K Units)
Table 98. Middle East and Africa Immunosuppressive Drugs Revenue by Type (2017-2022) & (US$ Million)
Table 99. Middle East and Africa Immunosuppressive Drugs Revenue by Type (2023-2028) & (US$ Million)
Table 100. Middle East and Africa Immunosuppressive Drugs Sales by Application (2017-2022) & (K Units)
Table 101. Middle East and Africa Immunosuppressive Drugs Sales by Application (2023-2028) & (K Units)
Table 102. Middle East and Africa Immunosuppressive Drugs Revenue by Application (2017-2022) & (US$ Million)
Table 103. Middle East and Africa Immunosuppressive Drugs Revenue by Application (2023-2028) & (US$ Million)
Table 104. Middle East and Africa Immunosuppressive Drugs Sales by Country (2017-2022) & (K Units)
Table 105. Middle East and Africa Immunosuppressive Drugs Sales by Country (2023-2028) & (K Units)
Table 106. Middle East and Africa Immunosuppressive Drugs Revenue by Country (2017-2022) & (US$ Million)
Table 107. Middle East and Africa Immunosuppressive Drugs Revenue by Country (2023-2028) & (US$ Million)
Table 108. Pfizer Corporation Information
Table 109. Pfizer Description and Major Businesses
Table 110. Pfizer Immunosuppressive Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 111. Pfizer Immunosuppressive Drugs Product Model Numbers, Pictures, Descriptions and Specifications
Table 112. Pfizer Recent Developments
Table 113. Sanofi Corporation Information
Table 114. Sanofi Description and Major Businesses
Table 115. Sanofi Immunosuppressive Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 116. Sanofi Immunosuppressive Drugs Product Model Numbers, Pictures, Descriptions and Specifications
Table 117. Sanofi Recent Developments
Table 118. Novartis Corporation Information
Table 119. Novartis Description and Major Businesses
Table 120. Novartis Immunosuppressive Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 121. Novartis Immunosuppressive Drugs Product Model Numbers, Pictures, Descriptions and Specifications
Table 122. Novartis Recent Developments
Table 123. Roche Corporation Information
Table 124. Roche Description and Major Businesses
Table 125. Roche Immunosuppressive Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 126. Roche Immunosuppressive Drugs Product Model Numbers, Pictures, Descriptions and Specifications
Table 127. Roche Recent Developments
Table 128. Astellas Pharma, Inc. Corporation Information
Table 129. Astellas Pharma, Inc. Description and Major Businesses
Table 130. Astellas Pharma, Inc. Immunosuppressive Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 131. Astellas Pharma, Inc. Immunosuppressive Drugs Product Model Numbers, Pictures, Descriptions and Specifications
Table 132. Astellas Pharma, Inc. Recent Developments
Table 133. GlaxoSmithKline plc Corporation Information
Table 134. GlaxoSmithKline plc Description and Major Businesses
Table 135. GlaxoSmithKline plc Immunosuppressive Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 136. GlaxoSmithKline plc Immunosuppressive Drugs Product Model Numbers, Pictures, Descriptions and Specifications
Table 137. GlaxoSmithKline plc Recent Developments
Table 138. Veloxis Pharmaceuticals Corporation Information
Table 139. Veloxis Pharmaceuticals Description and Major Businesses
Table 140. Veloxis Pharmaceuticals Immunosuppressive Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 141. Veloxis Pharmaceuticals Immunosuppressive Drugs Product Model Numbers, Pictures, Descriptions and Specifications
Table 142. Veloxis Pharmaceuticals Recent Developments
Table 143. Mylan Corporation Information
Table 144. Mylan Description and Major Businesses
Table 145. Mylan Immunosuppressive Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 146. Mylan Immunosuppressive Drugs Product Model Numbers, Pictures, Descriptions and Specifications
Table 147. Mylan Recent Developments
Table 148. Dr Reddys Laboratories Corporation Information
Table 149. Dr Reddys Laboratories Description and Major Businesses
Table 150. Dr Reddys Laboratories Immunosuppressive Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 151. Dr Reddys Laboratories Immunosuppressive Drugs Product Model Numbers, Pictures, Descriptions and Specifications
Table 152. Dr Reddys Laboratories Recent Developments
Table 153. Abbvie Inc Corporation Information
Table 154. Abbvie Inc Description and Major Businesses
Table 155. Abbvie Inc Immunosuppressive Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 156. Abbvie Inc Immunosuppressive Drugs Product Model Numbers, Pictures, Descriptions and Specifications
Table 157. Abbvie Inc Recent Developments
Table 158. Key Raw Materials Lists
Table 159. Raw Materials Key Suppliers Lists
Table 160. Immunosuppressive Drugs Distributors List
Table 161. Immunosuppressive Drugs Customers List
Table 162. Immunosuppressive Drugs Market Trends
Table 163. Immunosuppressive Drugs Market Drivers
Table 164. Immunosuppressive Drugs Market Challenges
Table 165. Immunosuppressive Drugs Market Restraints
Table 166. Research Programs/Design for This Report
Table 167. Key Data Information from Secondary Sources
Table 168. Key Data Information from Primary Sources
List of Figures
Figure 1. Immunosuppressive Drugs Product Picture
Figure 3. Global Immunosuppressive Drugs Market Share by Type in 2021 & 2028
Figure 3. Calcineurin Inhibitors Product Picture
Figure 4. Antiproliferative Agents Product Picture
Figure 5. mTOR Inhibitors Product Picture
Figure 6. Antibodies Product Picture
Figure 7. Steroids Product Picture
Figure 8. Global Immunosuppressive Drugs Market Share by Application in 2021 & 2028
Figure 9. Kidney Transplant
Figure 10. Bone Marrow Transplant
Figure 11. Liver Transplant
Figure 12. Heart Transplant
Figure 13. Lungs Transplant
Figure 14. Others Transplant
Figure 15. Immunosuppressive Drugs Report Years Considered
Figure 16. Global Immunosuppressive Drugs Sales 2017-2028 (K Units)
Figure 17. Global Immunosuppressive Drugs Revenue, (US$ Million), 2017 VS 2021 VS 2028
Figure 18. Global Immunosuppressive Drugs Revenue 2017-2028 (US$ Million)
Figure 19. Global Immunosuppressive Drugs Revenue Market Share by Region in Percentage: 2021 Versus 2028
Figure 20. Global Immunosuppressive Drugs Sales Market Share by Region (2017-2022)
Figure 21. Global Immunosuppressive Drugs Sales Market Share by Region (2023-2028)
Figure 22. North America Immunosuppressive Drugs Sales YoY (2017-2028) & (K Units)
Figure 23. North America Immunosuppressive Drugs Revenue YoY (2017-2028) & (US$ Million)
Figure 24. Europe Immunosuppressive Drugs Sales YoY (2017-2028) & (K Units)
Figure 25. Europe Immunosuppressive Drugs Revenue YoY (2017-2028) & (US$ Million)
Figure 26. Asia-Pacific Immunosuppressive Drugs Sales YoY (2017-2028) & (K Units)
Figure 27. Asia-Pacific Immunosuppressive Drugs Revenue YoY (2017-2028) & (US$ Million)
Figure 28. Latin America Immunosuppressive Drugs Sales YoY (2017-2028) & (K Units)
Figure 29. Latin America Immunosuppressive Drugs Revenue YoY (2017-2028) & (US$ Million)
Figure 30. Middle East & Africa Immunosuppressive Drugs Sales YoY (2017-2028) & (K Units)
Figure 31. Middle East & Africa Immunosuppressive Drugs Revenue YoY (2017-2028) & (US$ Million)
Figure 32. The Immunosuppressive Drugs Market Share of Top 10 and Top 5 Largest Manufacturers Around the World in 2021
Figure 33. The Top 5 and 10 Largest Manufacturers of Immunosuppressive Drugs in the World: Market Share by Immunosuppressive Drugs Revenue in 2021
Figure 34. Global Immunosuppressive Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2017 VS 2021
Figure 35. Global Immunosuppressive Drugs Sales Market Share by Type (2017-2028)
Figure 36. Global Immunosuppressive Drugs Revenue Market Share by Type (2017-2028)
Figure 37. Global Immunosuppressive Drugs Sales Market Share by Application (2017-2028)
Figure 38. Global Immunosuppressive Drugs Revenue Market Share by Application (2017-2028)
Figure 39. North America Immunosuppressive Drugs Sales Market Share by Type (2017-2028)
Figure 40. North America Immunosuppressive Drugs Revenue Market Share by Type (2017-2028)
Figure 41. North America Immunosuppressive Drugs Sales Market Share by Application (2017-2028)
Figure 42. North America Immunosuppressive Drugs Revenue Market Share by Application (2017-2028)
Figure 43. North America Immunosuppressive Drugs Sales Share by Country (2017-2028)
Figure 44. North America Immunosuppressive Drugs Revenue Share by Country (2017-2028)
Figure 45. United States Immunosuppressive Drugs Revenue (2017-2028) & (US$ Million)
Figure 46. Canada Immunosuppressive Drugs Revenue (2017-2028) & (US$ Million)
Figure 47. Europe Immunosuppressive Drugs Sales Market Share by Type (2017-2028)
Figure 48. Europe Immunosuppressive Drugs Revenue Market Share by Type (2017-2028)
Figure 49. Europe Immunosuppressive Drugs Sales Market Share by Application (2017-2028)
Figure 50. Europe Immunosuppressive Drugs Revenue Market Share by Application (2017-2028)
Figure 51. Europe Immunosuppressive Drugs Sales Share by Country (2017-2028)
Figure 52. Europe Immunosuppressive Drugs Revenue Share by Country (2017-2028)
Figure 53. Germany Immunosuppressive Drugs Revenue (2017-2028) & (US$ Million)
Figure 54. France Immunosuppressive Drugs Revenue (2017-2028) & (US$ Million)
Figure 55. U.K. Immunosuppressive Drugs Revenue (2017-2028) & (US$ Million)
Figure 56. Italy Immunosuppressive Drugs Revenue (2017-2028) & (US$ Million)
Figure 57. Russia Immunosuppressive Drugs Revenue (2017-2028) & (US$ Million)
Figure 58. Asia Pacific Immunosuppressive Drugs Sales Market Share by Type (2017-2028)
Figure 59. Asia Pacific Immunosuppressive Drugs Revenue Market Share by Type (2017-2028)
Figure 60. Asia Pacific Immunosuppressive Drugs Sales Market Share by Application (2017-2028)
Figure 61. Asia Pacific Immunosuppressive Drugs Revenue Market Share by Application (2017-2028)
Figure 62. Asia Pacific Immunosuppressive Drugs Sales Share by Region (2017-2028)
Figure 63. Asia Pacific Immunosuppressive Drugs Revenue Share by Region (2017-2028)
Figure 64. China Immunosuppressive Drugs Revenue (2017-2028) & (US$ Million)
Figure 65. Japan Immunosuppressive Drugs Revenue (2017-2028) & (US$ Million)
Figure 66. South Korea Immunosuppressive Drugs Revenue (2017-2028) & (US$ Million)
Figure 67. India Immunosuppressive Drugs Revenue (2017-2028) & (US$ Million)
Figure 68. Australia Immunosuppressive Drugs Revenue (2017-2028) & (US$ Million)
Figure 69. China Taiwan Immunosuppressive Drugs Revenue (2017-2028) & (US$ Million)
Figure 70. Indonesia Immunosuppressive Drugs Revenue (2017-2028) & (US$ Million)
Figure 71. Thailand Immunosuppressive Drugs Revenue (2017-2028) & (US$ Million)
Figure 72. Malaysia Immunosuppressive Drugs Revenue (2017-2028) & (US$ Million)
Figure 73. Latin America Immunosuppressive Drugs Sales Market Share by Type (2017-2028)
Figure 74. Latin America Immunosuppressive Drugs Revenue Market Share by Type (2017-2028)
Figure 75. Latin America Immunosuppressive Drugs Sales Market Share by Application (2017-2028)
Figure 76. Latin America Immunosuppressive Drugs Revenue Market Share by Application (2017-2028)
Figure 77. Latin America Immunosuppressive Drugs Sales Share by Country (2017-2028)
Figure 78. Latin America Immunosuppressive Drugs Revenue Share by Country (2017-2028)
Figure 79. Mexico Immunosuppressive Drugs Revenue (2017-2028) & (US$ Million)
Figure 80. Brazil Immunosuppressive Drugs Revenue (2017-2028) & (US$ Million)
Figure 81. Argentina Immunosuppressive Drugs Revenue (2017-2028) & (US$ Million)
Figure 82. Middle East and Africa Immunosuppressive Drugs Sales Market Share by Type (2017-2028)
Figure 83. Middle East and Africa Immunosuppressive Drugs Revenue Market Share by Type (2017-2028)
Figure 84. Middle East and Africa Immunosuppressive Drugs Sales Market Share by Application (2017-2028)
Figure 85. Middle East and Africa Immunosuppressive Drugs Revenue Market Share by Application (2017-2028)
Figure 86. Middle East and Africa Immunosuppressive Drugs Sales Share by Country (2017-2028)
Figure 87. Middle East and Africa Immunosuppressive Drugs Revenue Share by Country (2017-2028)
Figure 88. Turkey Immunosuppressive Drugs Revenue (2017-2028) & (US$ Million)
Figure 89. Saudi Arabia Immunosuppressive Drugs Revenue (2017-2028) & (US$ Million)
Figure 90. UAE Immunosuppressive Drugs Revenue (2017-2028) & (US$ Million)
Figure 91. Immunosuppressive Drugs Value Chain
Figure 92. Immunosuppressive Drugs Production Process
Figure 93. Channels of Distribution
Figure 94. Distributors Profiles
Figure 95. Bottom-up and Top-down Approaches for This Report
Figure 96. Data Triangulation
Figure 97. Key Executives Interviewed

---